{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:33:54Z","timestamp":1793162034217,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jocn.2026.112325","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:38:57Z","timestamp":1791391137000},"page":"112325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Baseline CSF and plasma glucocerebrosidase activity predict longitudinal cognitive decline in Parkinson\u2019s disease: A PPMI longitudinal cohort study"],"prefix":"10.1016","volume":"154","author":[{"given":"Emadoddin","family":"Kazemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jocn.2026.112325_b0005","article-title":"Cognitive impairment in parkinson's disease: an updated overview focusing on emerging pharmaceutical treatment approaches","volume":"59","author":"Degirmenci","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.jocn.2026.112325_b0010","article-title":"Profiling people with Parkinson's disease at risk of cognitive decline: Insights from PPMI and ICICLE-PD data","volume":"16","author":"Pourzinal","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"10.1016\/j.jocn.2026.112325_b0015","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/mds.28932","article-title":"GBA and APOE impact cognitive decline in parkinson's disease: a 10-Year population-based study","volume":"37","author":"Szwedo","year":"2022","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jocn.2026.112325_b0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.26359","article-title":"GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease","volume":"31","author":"Mata","year":"2016","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jocn.2026.112325_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-023-00373-x","article-title":"Early GCase activity is a predictor of long-term cognitive decline in Parkinson\u2019s disease","volume":"12","author":"Oftedal","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"4","key":"10.1016\/j.jocn.2026.112325_b0030","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","article-title":"Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with parkinson disease","volume":"100","author":"Oftedal","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jocn.2026.112325_b0035","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00702-022-02498-1","article-title":"Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice","volume":"129","author":"T\u00f6nges","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"10.1016\/j.jocn.2026.112325_b0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12974-023-02965-w","article-title":"Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease","volume":"20","author":"Gillett","year":"2023","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jocn.2026.112325_b0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","article-title":"Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"5","key":"10.1016\/j.jocn.2026.112325_b0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/acn3.52295","article-title":"Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD","volume":"12","author":"Gonzalez","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2026.112325_b0055","doi-asserted-by":"crossref","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","article-title":"Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease","volume":"8","author":"Atashrazm","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jocn.2026.112325_b0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: movement disorder society task force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2026.112325_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.134873","article-title":"Reduced plasma progranulin levels are associated with the severity of Parkinson\u2019s disease","volume":"725","author":"Yao","year":"2020","journal-title":"Neurosci Lett"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826004765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826004765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:50:08Z","timestamp":1793159408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826004765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":13,"alternative-id":["S0967586826004765"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112325","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline CSF and plasma glucocerebrosidase activity predict longitudinal cognitive decline in Parkinson\u2019s disease: A PPMI longitudinal cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112325"}}